Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction

Schizophrenia is characterized by reduced hippocampal volume, decreased dendritic spine density, altered neuroplasticity signaling pathways, and cognitive deficits associated with impaired hippocampal function. We sought to determine whether this diverse pathology could be linked to NMDA receptor (N...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 110; no. 26; pp. E2400 - E2409
Main Authors Balu, Darrick T, Li, Yan, Puhl, Matthew D, Benneyworth, Michael A, Basu, Alo C, Takagi, Shunsuke, Bolshakov, Vadim Y, Coyle, Joseph T
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 25.06.2013
National Acad Sciences
SeriesPNAS Plus
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Schizophrenia is characterized by reduced hippocampal volume, decreased dendritic spine density, altered neuroplasticity signaling pathways, and cognitive deficits associated with impaired hippocampal function. We sought to determine whether this diverse pathology could be linked to NMDA receptor (NMDAR) hypofunction, and thus used the serine racemase-null mutant mouse (SR ⁻/⁻), which has less than 10% of normal brain d -serine, an NMDAR coagonist. We found that d -serine was necessary for the maintenance of long-term potentiation in the adult hippocampal dentate gyrus and for full NMDAR activity on granule cells. SR ⁻/⁻ mice had reduced dendritic spines and hippocampal volume. These morphological changes were paralleled by diminished BDNF/Akt/mammalian target of rapamycin (mTOR) signaling and impaired performance on a trace-conditioning memory task. Chronic d -serine treatment normalized the electrophysiological, neurochemical, and cognitive deficits in SR ⁻/⁻ mice. These results demonstrate that NMDAR hypofunction can reproduce the numerous hippocampal deficits associated with schizophrenia, which can be reversed by chronic peripheral d -serine treatment.
Bibliography:http://dx.doi.org/10.1073/pnas.1304308110
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited* by Solomon H. Snyder, The Johns Hopkins University School of Medicine, Baltimore, MD, and approved May 7, 2013 (received for review March 5, 2013)
Author contributions: D.T.B., Y.L., M.D.P., M.A.B., A.C.B., V.Y.B., and J.T.C. designed research; D.T.B., Y.L., M.D.P., M.A.B., and S.T. performed research; D.T.B., Y.L., and M.D.P. analyzed data; and D.T.B., Y.L., M.D.P., V.Y.B., and J.T.C. wrote the paper.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.1304308110